fda approval in tgct, breakthrough designation in melanoma, and more
Published 4 years ago • 347 plays • Length 9:11Download video MP4
Download video MP3
Similar videos
-
10:01
fda approval in ctcl, breakthrough therapy designation in crc, and more
-
9:57
fda approvals in fl and rcc, breakthrough designation in myeloma, and more
-
6:23
adjuvant ipilimumab approval, two breakthrough designations, and more
-
9:38
fda approval in rcc, odac meetings scheduled in tgct and aml, and more
-
0:55
dr. richard pazdur on the breakthrough designation requirements
-
11:38
priority review designation in tgct, bla submitted in her2 breast cancer, and more
-
6:31
patient registry data demonstrates chronic nature of tgct symptoms
-
1:18
dr. eward on the unmet need for novel agents for tgct and sarcoma
-
1:57
dr. randall on using pexidartinib to treat tenosynovial giant cell tumor
-
6:53
tenosynovial giant cell tumors (tgct) explained
-
0:59
the treatment of patients with t(11;14) myeloma
-
1:00
the recent fda approval of teclistamab for r/r multiple myeloma
-
2:57
identifying patients for neoadjuvant melanoma therapy
-
4:09
tsgct: establishing a differential diagnosis
-
57:53
new treatment updates for tgct
-
0:50
prognostic factors for mtc
-
25:34
novel immunotherapies and combinations